Oncology

Two scientists working in a research laboratory
#Cancer Research UK #Oncology #Peptides #Phase II trial #Rare cancers

UK-Norwegian collaboration to trial peptide for rare cancer

Cancer Research UK, Cytovation and the Norwegian Cancer Society have signed an agreement to bring Cytovation’s lead asset, CY-101, into a multi-national Phase II clinical trial for patients with adrenocortical carcinoma (ACC).  CY-101, developed by Cytovation, is a synthetic peptide with a dual function. It selectively targets… Read More

#Business & Investment #Cancer Research #News

Non-small cell lung cancer
#Bispecific Antibodies #European Commission #Johnson & Johnson #Non-small cell lung cancer (NSCLC) #Oncology

Bispecific antibody combo for NSCLC could extend life by a year

The European Commission (EC) has approved a Marketing Authorisation (MA) for Lazcluze (lazertinib), in combination with Rybrevant (amivantamab).  It is approved for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or exon… Read More

#News #Regulatory

Cancer cells
#Antibody drug conjugate (ADC) #AstraZeneca #Breast cancer #Daiichi Sankyo #FDA #Oncology

FDA approved ADC improves breast cancer survival by 37%

The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan-dlnk (Datroway) a Trop-2-directed antibody and topoisomerase inhibitor conjugate, as a treatment for breast cancer.  The decision was based on the results of the Phase III TROPION-Breast01 trial which showed a 37% reduction in the risk of… Read More

#News #Regulatory

FDA
#AstraZeneca #FDA #Lymphoma #Oncology

First US approval for first-line BTK inhibitor for mantle cell lymphoma

The US Food and Drug Administration (FDA) has granted approval to acalabrutinib (Calquence) with bendamustine and rituximab for adults with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT).  The regulator also granted approval to acalabrutinib as a single agent… Read More

#News #Regulatory #Trending News

Colorectal cancer
#Barts Institute #Bowel cancer #Colorectal cancer #Immunotherapy #Oncology #The Francis Crick Institute

CD74 level predicts immunotherapy response in bowel cancer

The amount of a protein called CD74 can indicate which people with bowel cancer may respond best to immunotherapy, new research has revealed.  If integrated into the clinic, the researchers at the Francis Crick Institute and Barts Cancer Institute, Queen Mary University of London, say testing for… Read More

#Cancer Research #News #Trending News

Scan to diagnose head and neck cancer
#Cancer vaccine #Head and neck cancer #Oncology #Phase II trial #Scancell Holdings

Vaccine achieves early clinical validation in head and neck cancer

The combination of Scancell’s Modi-1 and a checkpoint blockade has shown promise in HPV negative head and neck squamous cell carcinoma (SCCHN) in an ongoing Phase IIa study.  The Phase IIa dose expansion ModiFY study is evaluating the safety, tolerability, and preliminary efficacy of Modi-1 in combination… Read More

#Cancer Research #News

Salivary glands
#Avacta #Head and neck cancer #Oncology #Peptide-drug conjugate #Phase I trial

Avacta’s peptide drug conjugate shrinks tumours in salivary gland cancer

Avacta has announced positive early efficacy data for its peptide drug conjugate, AVA6000, demonstrating clinically meaningful tumour shrinkage in patients with salivary gland cancer (SGC).  AVA6000 consists of doxorubicin chemotherapy conjugated with Avacta’s pre|CISION peptide, specifically cleaved by fibroblast activation protein-alpha (FAP) in the tumour microenvironment. Read More

#Cancer Research #Editor's Choice #News

Bispecific antibodies
#Bispecific Antibodies #Bispecific therapeutics #Daiichi Sankyo #Oncology #Partnership #Solid tumours

Partners invite proposals for multi-functional biologics research

Daiichi Sankyo and German research institute BioMed X have agreed a new partnership to advance the development of bi- and multi-specific biologics for treating solid tumours.  The new project, entitled ‘New Strategies for Targeting of Solid Tumours with Multi-Specific Biologics (MTT; Multi-Specific Targeting of Tumours)’, will be… Read More

#Business & Investment #News

Gastrointestinal tract
#Gastrointestinal #GSK #Mergers and acquisitions #Oncology

GSK grows gastrointestinal cancers portfolio with new acquisition

GSK has revealed it will acquire IDRx, a Boston-based, clinical-stage biopharmaceutical company developing precision therapeutics for the treatment of gastrointestinal stromal tumours (GIST).  Under the agreement, GSK will pay $1 billion upfront, with potential for an additional $150 million success-based regulatory approval milestone payment.   The… Read More

#Business & Investment #Cancer Research #News

Cancer cells
#AstraZeneca #Cancer research #Guide #Immune response #Immuno-oncology #Immunotherapy #Immutep #Interview #Oncology #OncologyCancer research

Podcast: Breakthroughs and opportunities in cancer research

This is the latest episode of the free DDW narrated podcast, titled “Where are the global breakthroughs, opportunities and developments in cancer research?”, which covers three articles written for DDW Volume 24 – Issue 2, Spring 2023 of DDW. They are called: “Global breakthroughs in cancer drug discovery”, “… Read More

#News

#Artificial intelligence (AI) #Oncology #Sentinal4D #Spinout #Start-ups #The Institute of Cancer Research

Precision oncology spinout hopes to expedite drug discovery

Sentinal4D, a spinout company from The Institute of Cancer Research (ICR), London, has been announced to the public after closing its first round of funding.  The new company aims to accelerate drug discovery and development to target drugs to patients, using patented artificial intelligence-driven methods for personalised… Read More

#Business & Investment #News #Start-up Zone

Test for KRAS mutation
#Antibody #Combination therapy #KRAS #Oncology #University of California San Francisco

Precision drug, antibody and radiation therapy kills tumours

Scientists have found a way to combine a precision drug therapy with an antibody and radiation to eliminate tumours without causing side effects.  “This is a one-two punch,” said Charly Craik, Professor of Pharmaceutical Chemistry at University of California, San Francisco (UCSF) and co-senior author of the… Read More

#News #Trending News

Magic Mushrooms in laboratory. Psilocybin science and research.
#Alcohol Use Disorder #Mental health #Oncology #Psilocybin #Psychedelics #Psychiatry

Findings support positive mental health benefits of psychedelics

One or two doses of psilocybin may improve the mental health of cancer patients when accompanied by psychotherapy, a new report suggests.   A second new study found that treatment with psilocybin resulted in lasting, positive personality changes in patients with alcohol use disorder.  In the… Read More

#News

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Collaboration #Innovent #Lung cancer #Oncology #Roche #Small cell lung cancer

Roche pays $80 million for Innovent’s lung cancer ADC

Roche and Innovent Biologics have agreed a collaboration and exclusive license agreement to develop antibody drug conjugate (ADC) IBI3009 for advanced small cell lung cancer.  Under the agreement, the two parties will jointly focus on the early-stage development of the ADC candidate, after which Roche will take… Read More

#Business & Investment #News

Medical professional examining mammogram
#Breast cancer #Molecular glue degrader #Monte Rosa Therapeutics #Oncology

Selective oral CDK2 degrader shows promise in breast cancer models

According to new data, a cyclin-dependent kinase 2 (CDK2)-directed molecular glue degrader (MGD) drove deep tumour regression in preclinical models of HR-positive/HER2-negative breast cancer.  Monte Rosa Therapeutics will present the preclinical data at the 2024 San Antonio Breast Cancer Symposium, held 10-13 December in San Antonio, Texas. Read More

#Cancer Research #News